每(mei)經(jing)AI快訊，方(fang)盛(sheng)制藥(yao)（SH 603998，收盤價：8.01元）12月(yue)30日(ri)晚間發布公告稱，截至本公告披(pi)露日(ri)，張慶(qing)華(hua)先生(sheng)(sheng)(sheng)(sheng)(sheng)(sheng)直(zhi)接持有公司的(de)股(gu)(gu)(gu)(gu)(gu)份(fen)(fen)總(zong)(zong)數(shu)(shu)約(yue)為(wei)1.56億(yi)(yi)股(gu)(gu)(gu)(gu)(gu)，占公司股(gu)(gu)(gu)(gu)(gu)份(fen)(fen)總(zong)(zong)數(shu)(shu)（約(yue)4.4億(yi)(yi)股(gu)(gu)(gu)(gu)(gu)）的(de)35.49%；張慶(qing)華(hua)先生(sheng)(sheng)(sheng)(sheng)(sheng)(sheng)質(zhi)(zhi)押的(de)公司股(gu)(gu)(gu)(gu)(gu)份(fen)(fen)總(zong)(zong)數(shu)(shu)約(yue)為(wei)1.24億(yi)(yi)股(gu)(gu)(gu)(gu)(gu)，占其(qi)直(zhi)接持有公司股(gu)(gu)(gu)(gu)(gu)份(fen)(fen)總(zong)(zong)數(shu)(shu)的(de)79.75%，占公司股(gu)(gu)(gu)(gu)(gu)份(fen)(fen)總(zong)(zong)數(shu)(shu)的(de)28.31%；張慶(qing)華(hua)先生(sheng)(sheng)(sheng)(sheng)(sheng)(sheng)控股(gu)(gu)(gu)(gu)(gu)的(de)湖南開舜投(tou)(tou)(tou)資(zi)咨詢有限(xian)公司之控股(gu)(gu)(gu)(gu)(gu)子公司堆龍德(de)慶(qing)共(gong)生(sheng)(sheng)(sheng)(sheng)(sheng)(sheng)創業投(tou)(tou)(tou)資(zi)管理(li)有限(xian)公司持有公司股(gu)(gu)(gu)(gu)(gu)份(fen)(fen)數(shu)(shu)約(yue)為(wei)1443萬股(gu)(gu)(gu)(gu)(gu)，共(gong)生(sheng)(sheng)(sheng)(sheng)(sheng)(sheng)投(tou)(tou)(tou)資(zi)質(zhi)(zhi)押的(de)公司股(gu)(gu)(gu)(gu)(gu)份(fen)(fen)總(zong)(zong)數(shu)(shu)為(wei)0股(gu)(gu)(gu)(gu)(gu)；綜上，張慶(qing)華(hua)先生(sheng)(sheng)(sheng)(sheng)(sheng)(sheng)及其(qi)一致行動人(ren)共(gong)生(sheng)(sheng)(sheng)(sheng)(sheng)(sheng)投(tou)(tou)(tou)資(zi)合計(ji)持有公司約(yue)1.7億(yi)(yi)股(gu)(gu)(gu)(gu)(gu)，以此計(ji)算(suan)，張慶(qing)華(hua)先生(sheng)(sheng)(sheng)(sheng)(sheng)(sheng)及其(qi)一致行動人(ren)共(gong)生(sheng)(sheng)(sheng)(sheng)(sheng)(sheng)投(tou)(tou)(tou)資(zi)合計(ji)質(zhi)(zhi)押的(de)公司股(gu)(gu)(gu)(gu)(gu)份(fen)(fen)總(zong)(zong)數(shu)(shu)約(yue)為(wei)1.24億(yi)(yi)股(gu)(gu)(gu)(gu)(gu)，占持股(gu)(gu)(gu)(gu)(gu)總(zong)(zong)數(shu)(shu)的(de)73%。

2022年1至6月份，方盛制藥(yao)(yao)的營業(ye)收入構成為：工業(ye)占比(bi)(bi)76.49%，醫療行業(ye)占比(bi)(bi)16.52%，醫藥(yao)(yao)商(shang)業(ye)占比(bi)(bi)3.34%，其他占比(bi)(bi)1.25%。

方盛制藥的總裁、董事長均是周曉莉，女，49歲，學歷背(bei)景(jing)為大專。

截(jie)至發稿，方(fang)盛制藥市值為35億(yi)元。

道達號（daoda1997）“個股趨勢”提醒(xing)：
1. 近30日內無機構對方盛制藥進行調研。
更多(duo)個股趨勢信息，請搜(sou)索(suo)微信公眾號“道(dao)達號”，回復“查詢(xun)”，領取免費查詢(xun)權(quan)限！

每經頭條（nbdtoutiao）——

(記者 蔡鼎)

免責聲(sheng)明：本文內容與數據僅供參考，不構成投資(zi)建議，使用(yong)前請(qing)核實。據此操作(zuo)，風險(xian)自擔。